Review of the use of Topiramate for treatment of psychiatric disorders
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background: Topiramate is a new antiepileptic drug, originally designed as an oral hypoglycaemic subsequently approved as anticonvulsant. It has increasingly been used in the treatment of numerous psychiatric conditions and it has also been associated with weight loss potentially relevant in reversing weight gain induced by psychotropic medications. This article reviews pharmacokinetic and pharmacodynamic profile of topiramate, its biological putative role in treating psychiatric disorders and its relevance in clinical practice. Methods: A comprehensive search from a range of databases was conducted and papers addressing the topic were selected. Results: Thirty-two published reports met criteria for inclusion, 4 controlled and 28 uncontrolled studies. Five unpublished controlled studies were also identified in the treatment of acute mania. Conclusions: Topiramate lacks efficacy in the treatment of acute mania. Increasing evidence, based on controlled studies, supports the use of topiramate in binge eating disorders, bulimia nervosa, alcohol dependence and possibly in bipolar disorders in depressive phase. In the treatment of rapid cycling bipolar disorders, as adjunctive treatment in refractory bipolar disorder in adults and children, schizophrenia, posttraumatic stress disorder, unipolar depression, emotionally unstable personality disorder and Gilles de la Tourette's syndrome the evidence is entirely based on open label studies, case reports and case series. Regarding weight loss, findings are encouraging and have potential implications in reversing increased body weight, normalisation of glycemic control and blood pressure. Topiramate was generally well tolerated and serious adverse events were rare.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382 · cited 1×
“In psychiatry, drug induced severe obesity plays an important role [62] and substantive weight gain has been described with several psychotropic medications [63-65].”
Calabrese, J. R., Bowden, C. L., Sachs, G. S., Ascher, J. A., Monaghan, E., Rudd, G. D., & The Lamictal 602 Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0203 · Cited by 1,054
Oral topiramate for treatment of alcohol dependence: A randomised controlled trial
Johnson, B. A., Ait-Daoud, N., Bowden, C. L., DiClemente, C. C., Roache, J. D., Lawson, K., Javors, M. A., & Ma, J. Z. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13370-3 · Cited by 743
Bowden, C. L. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.5.481 · Cited by 678 · cited 1×
“The efficacy of lithium, valproate, and carbamazapine in prophylaxis of bipolar spectrum disorders is rather modest [19-22].”
The Glutamatergic Dysfunction Hypothesis for Schizophrenia
Coyle, J. T. (1996) · Harvard Review of Psychiatry · doi:10.3109/10673229609017192 · Cited by 568 · cited 2×
“Elevated levels of N-acetyl-aspartyl-glutamate could rise from diminished activity of glutamate carboxypeptidase II, a hydrolytic enzyme enriched at glutamatergic nerve terminals and located on the membrane of astrocytes [ 35 ,38].”
Calabrese, J. R., Suppes, T., Bowden, C. L., Sachs, G. S., Swann, A. C., McElroy, S. L., Kusumakar, V., Ascher, J. A., Earl, N. L., Greene, P. L., et al. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1106 · Cited by 498
McElroy, S. L., Arnold, L. M., Shapira, N. A., Keck, P. E., Rosenthal, N. R., Karim, M. R., Kamin, M., & Hudson, J. I. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.255 · Cited by 484 · cited 4×
“[96] designed a randomized, placebo-controlled trial, investigating the therapeutic benefit of topiramate in treating binge eating disorder associated with obesity.”
Influential(1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820020059008 · Cited by 371
Bray, G. A., Hollander, P., Klein, S., Kushner, R., Levy, B., Fitchet, M., & Perry, B. H. (2003) · Obesity Research · doi:10.1038/oby.2003.102 · Cited by 344
Cited by
Swann, A. C. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05146.x · Cited by 109
Motaghinejad, M., Motevalian, M., Fatima, S., Beiranvand, T., & Mozaffari, S. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1771-2 · Cited by 57
Motaghinejad, M., Motevalian, M., Falak, R., Heidari, M., Sharzad, M., & Kalantari, E. (2016) · Journal of Neural Transmission · doi:10.1007/s00702-016-1619-1 · Cited by 49
Gray, J. C., Treloar Padovano, H., Wemm, S. E., & Miranda, R. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000843 · Cited by 18
Metadata
- Authors
- Arnone, D.
- Venue
- Annals of General Psychiatry
- Published
- 2005-02-16
- Volume
- 4
- Issue
- 1
- Pages
- 5-5
- ISSN
- 1744-859X (ISSN-L)
- OpenAlex
- W1531379989
- Cited by
- 134
- References
- 9
- FWCI
- 6.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Review of the use of Topiramate for treatment of psychiatric disorders. https://app.cochat.ai/papers/10.1186/1744-859x-4-5
- The paper
- Arnone, D. (2005). Review of the use of Topiramate for treatment of psychiatric disorders. Annals of General Psychiatry. https://doi.org/10.1186/1744-859x-4-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.